XML 48 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jul. 05, 2016
Sep. 30, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Financial assets and liabilities subject to fair value measurements              
Transfer of assets from Level 1 to Level 2     $ 0   $ 0    
Transfer of assets from Level 2 to Level 1     0   0    
Assets:              
Fair value of assets     191,758   191,758   $ 144,754
Liabilities:              
Contingent consideration payable     265,350   265,350   269,722
Derivative liability             265
Deferred compensation plan liability     1,994   1,994   1,479
Fair value of liabilities     267,344   267,344   271,466
Contingent consideration payable     265,350   265,350   269,722
Contingent consideration payable              
Balance, beginning of the period     274,300 $ 277,229 269,722 $ 274,077  
Payment of contingent consideration in cash     (10,000) (5,000) (10,000) (5,000)  
Payment of contingent consideration in stock       (6,115)   (6,115)  
Unrealized change in fair value change during the period, included in Statement of Operations     1,050 10,186 5,628 13,338  
Balance, end of the period     265,350 $ 276,300 265,350 $ 276,300  
Other current liabilities              
Foreign Currency Exchange Rate Exposure              
Derivative liabilities     0   0   300
Scioderm              
Liabilities:              
Contingent consideration payable   $ 259,000 254,700   254,700    
Contingent consideration payable   $ 259,000 254,700   254,700    
MiaMed Inc              
Contingent consideration payable              
Asset acquisition, potential aggregate deal value $ 89,500            
Clinical and Regulatory Approval milestones | Scioderm              
Liabilities:              
Contingent consideration payable     228,100   228,100    
Contingent consideration payable     228,100   228,100    
Revenue-based milestones | Scioderm              
Liabilities:              
Contingent consideration payable     26,600   26,600    
Contingent consideration payable     26,600   26,600    
Minimum | Clinical and Regulatory Approval milestones | Scioderm              
Liabilities:              
Discount rate (as a percent)   0.40%          
Minimum | Revenue-based milestones | Scioderm              
Liabilities:              
Discount rate (as a percent)   1.00%          
Maximum | Clinical and Regulatory Approval milestones | Scioderm              
Liabilities:              
Discount rate (as a percent)   1.10%          
Maximum | Clinical and Regulatory Approval milestones | MiaMed Inc              
Contingent consideration payable              
Contingent consideration payable upon achievement of milestones 83,000            
Maximum | Revenue-based milestones | Scioderm              
Liabilities:              
Discount rate (as a percent)   2.20%          
Maximum | Clinical, Regulatory and Commercial milestones | MiaMed Inc              
Contingent consideration payable              
Contingent consideration payable upon achievement of milestones $ 83,000            
ATB200 Pompe program | Clinical and Regulatory Approval milestones | Callidus              
Liabilities:              
Contingent consideration payable     10,300   10,300    
Contingent consideration payable     10,300   10,300    
Commercial paper              
Assets:              
Fair value of assets     80,789   80,789   68,390
Corporate debt securities              
Assets:              
Fair value of assets     108,649   108,649   74,535
Money market              
Assets:              
Fair value of assets     2,320   2,320   1,829
Level 2              
Assets:              
Fair value of assets     191,758   191,758   144,754
Liabilities:              
Derivative liability             265
Deferred compensation plan liability     1,994   1,994   1,479
Fair value of liabilities     1,994   1,994   1,744
Level 2 | Commercial paper              
Assets:              
Fair value of assets     80,789   80,789   68,390
Level 2 | Corporate debt securities              
Assets:              
Fair value of assets     108,649   108,649   74,535
Level 2 | Money market              
Assets:              
Fair value of assets     2,320   2,320   1,829
Level 3              
Liabilities:              
Contingent consideration payable     265,350   265,350   269,722
Fair value of liabilities     265,350   265,350   269,722
Contingent consideration payable     $ 265,350   $ 265,350   $ 269,722
Level 3 | Revenue-based milestones | Monte Carlo | Scioderm              
Liabilities:              
Probability of achievement of milestones (as a percent)         66.50%    
Revenue volatility (as a percent)         51.00%    
Level 3 | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm              
Liabilities:              
Discount rate (as a percent)         1.00%    
Probability of achievement of milestones (as a percent)         66.50%    
Level 3 | Minimum | Revenue-based milestones | Monte Carlo | Scioderm              
Liabilities:              
Discount rate (as a percent)         1.50%    
Level 3 | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Scioderm              
Liabilities:              
Discount rate (as a percent)         1.30%    
Probability of achievement of milestones (as a percent)         70.00%    
Level 3 | Maximum | Revenue-based milestones | Monte Carlo | Scioderm              
Liabilities:              
Discount rate (as a percent)         2.40%    
Level 3 | ATB200 Pompe program | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus              
Liabilities:              
Discount rate (as a percent)         12.50%    
Level 3 | ATB200 Pompe program | Minimum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus              
Liabilities:              
Probability of achievement of milestones (as a percent)         32.00%    
Level 3 | ATB200 Pompe program | Maximum | Clinical and Regulatory Approval milestones | Probability weighted discounted cash flow | Callidus              
Liabilities:              
Probability of achievement of milestones (as a percent)         45.00%